Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

Xanderzzzzzzz Sep. 13 at 2:19 PM

$CATX

0 · Reply

Xanderzzzzzzz Sep. 13 at 12:01 PM

$CATX Did you know?----> Perspective’s proprietary chelator retains ~95% of 212Bi after transition in drug formulation !!!!!

0 · Reply

Xanderzzzzzzz Sep. 13 at 11:59 AM

$CATX Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product !!!!!!!!!!!!

0 · Reply

Xanderzzzzzzz Sep. 13 at 1:42 AM

$CATX

0 · Reply

Alacrity2 Sep. 12 at 11:29 PM

$CATX a month old but still interesting https://www.globenewswire.com/news-release/2025/08/13/3132411/0/en/Perspective-Therapeutics-Provides-Recent-Business-Highlights-and-Reports-2Q-2025-Results.html

0 · Reply

RunnerSignals Sep. 12 at 9:50 PM

$CATX $MIST $EFTY $PACS $AEVA These Comeback Kings hit rock bottom then said "watch this". Friday finishes belong to the fearless https://stocksrunner.com/news/2025-09-12-comeback-kings-rule-fridays-close

1 · Reply

JDinvestments Sep. 12 at 8:01 PM

$CATX nice close just like yesterday STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

JDinvestments Sep. 12 at 5:58 PM

$CATX morty the moron spewing his 🤬🤬🤬 STRONG BUYOUT 👋👋👋🤡🤡🤡💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

jto2 Sep. 12 at 4:19 PM

$CATX Biotech is a wild ride — invest only with deep DD and money you can afford to forget, and sometimes the smartest move is to cut losses, use them for taxes, and move on, because holding long without conviction is punishment.

3 · Reply

morty104 Sep. 12 at 2:30 PM

$CATX where’s Pumpy Pumperton? Wake up and grab your Pom Poms. You’re on next….

0 · Reply

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Aug 26, 2025, 7:00 AM EDT - 18 days ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 13, 2025, 6:45 AM EDT - 4 weeks ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 2, 2025, 8:53 AM EDT - 6 weeks ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Jul 24, 2025, 12:45 PM EDT - 7 weeks ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 2 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 3 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 3 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 3 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 5 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 6 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 6 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 7 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 7 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 7 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 8 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 8 months ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 9 months ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 9 months ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 10 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 10 months ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 10 months ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 10 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 1 year ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Jun 11, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Jun 10, 2024, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

May 24, 2024, 8:01 AM EDT - 1 year ago

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 20, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

May 15, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Xanderzzzzzzz Sep. 13 at 2:19 PM

$CATX

0 · Reply

Xanderzzzzzzz Sep. 13 at 12:01 PM

$CATX Did you know?----> Perspective’s proprietary chelator retains ~95% of 212Bi after transition in drug formulation !!!!!

0 · Reply

Xanderzzzzzzz Sep. 13 at 11:59 AM

$CATX Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product !!!!!!!!!!!!

0 · Reply

Xanderzzzzzzz Sep. 13 at 1:42 AM

$CATX

0 · Reply

Alacrity2 Sep. 12 at 11:29 PM

0 · Reply

RunnerSignals Sep. 12 at 9:50 PM

1 · Reply

JDinvestments Sep. 12 at 8:01 PM

$CATX nice close just like yesterday STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

JDinvestments Sep. 12 at 5:58 PM

$CATX morty the moron spewing his 🤬🤬🤬 STRONG BUYOUT 👋👋👋🤡🤡🤡💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

jto2 Sep. 12 at 4:19 PM

3 · Reply

morty104 Sep. 12 at 2:30 PM

$CATX where’s Pumpy Pumperton? Wake up and grab your Pom Poms. You’re on next….

0 · Reply

RadioIsotope25 Sep. 12 at 12:39 PM

$RADX $CHRS $CATX

0 · Reply

jto2 Sep. 11 at 4:53 PM

If $CATX delivers today, rumors about it becoming the new SOC could attract serious buyers.

1 · Reply

markbass2341 Sep. 11 at 4:01 PM

$CATX all I can say is don’t get your hopes up …. This is pure manipulation by Friday 3 PM. It will be back in the toilet.

1 · Reply

Biotechinvestor101 Sep. 11 at 11:19 AM

$CATX I keep buying at these prices. Expect update of trials at ESMO meeting in October

0 · Reply

Hoosiers01 Sep. 10 at 11:49 PM

$CATX - here we go again - $.32 - can you say Dejavu… are we heading back to $.18-.20 - maybe

0 · Reply

JDinvestments Sep. 10 at 8:28 PM

$CATX I’ll just keep adding has paid off in the past sub $5 or .5 pre split has always worked out 🔥🔥🔥 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

JDinvestments Sep. 10 at 8:04 PM

$CATX with institutional and insiders controlling approx 85% of float who’s playing with PPS ??? Are they really coming after the bit of retail left ??? STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

1 · Reply

Miura1957 Sep. 10 at 5:39 PM

$CATX I want to believe that something great will happen at the conference tomorrow, but my gut tells me it will not. This will rise when the market wants it to and I don’t think it will correlate to any release…I am often wrong and hope I am this time….sure been waiting long enough.

1 · Reply

AG80Rider Sep. 10 at 5:16 PM

$CATX do we have today meeting with Oppenheimer right?

0 · Reply

jto2 Sep. 10 at 5:14 PM

The stock has been a “stealth play,” but after tomorrow that may change. With $CATX featured on two key panels at the OPCO summit—hosted by Oppenheimer—it feels like the perfect setup to finally shed its “hidden gem” label. And with CATX’s new CFO, Joel Sendek, a former top analyst at Oppenheimer, this appearance looks less like a routine presentation and more like a strategic, high-profile debut.

1 · Reply

Xanderzzzzzzz Sep. 10 at 4:20 PM

$CATX

0 · Reply

Xanderzzzzzzz Sep. 10 at 11:48 AM

$CATX

0 · Reply

Market Cap	251.01M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	806,600
Avg Vol	777,234
Day's Range	N/A - N/A
Shares Out	74.26M
Stochastic %K	43%
Beta	1.20
Analysts	Strong Sell
Price Target	$12.92